Hatch-Waxman Improvement Act of 2022
This bill extends through FY2026 provisions that establish a period of market exclusivity for certain new drugs with single enantiomers (i.e., one of a pair of molecules that are mirror images of one another).
To reauthorize a provision of the Federal Food, Drug, and Cosmetic Act 
           pertaining to drugs containing single enantiomers.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Hatch-Waxman Improvement Act of 
2022''.

SEC. 2. REAUTHORIZATION OF PROVISION PERTAINING TO DRUGS CONTAINING 
              SINGLE ENANTIOMERS.

    Section 505(u) of the Federal Food, Drug, and Cosmetic Act (21 
U.S.C. 355(u)) is amended--
            (1) in paragraph (1)(A)(ii)(II), by adding ``(other than 
        bioavailability studies)'' after ``any clinical 
        investigations''; and
            (2) in paragraph (4), by striking ``October 1, 2022'' and 
        inserting ``October 1, 2027''.
                                 <all>
Hatch-Waxman Improvement Act of 2022
A bill to reauthorize a provision of the Federal Food, Drug, and Cosmetic Act pertaining to drugs containing single enantiomers.
Hatch-Waxman Improvement Act of 2022
Sen. Marshall, Roger